AMDL Signs Exclusive Licensing Agreement for Human Papilloma Virus Diagnostic Test Kit in Certain Asian CountriesAmdl Inc • April 3rd, 2008 • Surgical & medical instruments & apparatus
TUSTIN, Calif., April 3, 2008 — AMDL, Inc. (Amex: ADL — News), headquartered in Tustin, California, with operations in Shenzhen, Jiangxi, and Jilin, China, is a vertically integrated specialty pharmaceutical company. In combination with its subsidiary Jade Pharmaceutical Inc. (“JPI”), AMDL engages in the research, development, manufacture, and marketing of diagnostic products. Today, AMDL announced that it has entered into an exclusive sublicense (subject to certain terms and conditions) agreement with MyGene International, Inc. (“MGI,” USA) for the MyGene HPV Chip Kit, a diagnostic product for in-vitro genotype testing in women of the Human Papilloma Virus (HPV). The agreement between MGI and AMDL is an exclusive sublicense to use the patents, trademark, and technology in manufacturing, promoting, marketing, distributing, and selling the MyGene HPV Test Kit in the countries of China (including Hong Kong), Taiwan, Singapore, Malaysia, Thailand, Cambodia, and Vietnam. MGI owns an exclus
PRODUCT LICENSE, DISTRIBUTION AND MANUFACTURING AGREEMENTProduct License, Distribution and Manufacturing Agreement • April 3rd, 2008 • Amdl Inc • Surgical & medical instruments & apparatus
This Agreement (this “Agreement”), effective this 28th day of March, 2008, by and between MYGENE INTERNATIONAL, INC. (“MGI”), a Utah corporation, having its principal place of business at 7651 South 700 West, Suite 102, Midvale, Utah, 84047, USA and AMDL, INC. (“AMDL”), a Delaware corporation, having its principal place of business at 2492 Walnut Ave., Suite 100, Tustin CA 92780-6953, USA. MGI and AMDL may hereinafter each be referred to as a “Party” or collectively as the “Parties.”
